NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, today announced that it has initiated the second of its two pivotal trials of Vilazodone, the Company’s novel drug candidate for the treatment of depression. This double-blind, placebo-controlled clinical trial is designed to assess the efficacy and safety of Vilazodone. It will also further evaluate genetic biomarkers of response to Vilazodone, which may lead to the development of a pharmacogenetic test that would help determine the likelihood of a patient’s positive response to the drug.
